Retatrutide Dosage Calculator & Clinical Trial Protocols Guide

Retatrutide Dosing: What Gets Overlooked in the Headlines

Retatrutide is an investigational engineered weight-loss peptide that switches on three metabolic receptors at once: GIP, GLP-1, and glucagon. In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver.¹ ⁶

In the Phase III 80-week obesity trial (TRIUMPH-1) of 2,300 adults (avg 40 BMI), 12 mg produced 28% weight loss and 9 mg reached 26%. A heavier subgroup carried on through 104 weeks, with both 12mg and 9mg groups reaching ~30% total weight lost from baseline.

What gets lost from the headlines is the trial population lens — Retatrutide's unique pharmacology, and its shared characteristics with other GLP-1 weight-loss drugs affect different populations in meaningfully different ways. If an individual does not match the characteristics of the clinical trial populations, the experience at the same doses, the same titration schedules, will be materially different.

Dose Exposure: Starting Weight Matters

A lighter body has less blood and tissue to spread the same dose through, leaving more of the drug free to reach receptors. While reta-specific numbers are not yet published, the rest of the GLP-1 class is well measured: in the semaglutide and tirzepatide population studies, a 120 to 155 lb person gets roughly 20 to 50% more drug exposure than the 185 lb reference, and a 265 lb person gets 25 to 30% less.⁹ In plain terms, a 155 lb person's 1 mg behaves closer to what the 240 lb trial cohort got at 1.5 mg.

Dose Response: Metabolically Healthy Individuals Have a Distinct Experience

Even after adjusting for weight-based dose exposure, retatrutide's receptor engagement produces a different effect depending on the body it lands in. Heart rate is the clearest case.

In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo¹. However, in a healthy lean group from the phase 1b, the same 1 mg raised heart rate by about +10 bpm, with a peak near +15 to +20 bpm around days 4 to 6¹⁶.

Same dose, same drug, a different cardiovascular system reading it: lean, healthier, and younger have more reactive heart-rate control, while sedentary, obese and metabolically stressed populations have a blunted system.

Retatrutide's GLP-1, GIP, and Glucagon Receptor Profiles Do Not Scale Equally

Many drugs do more of the same thing as the dose goes up. Retatrutide does not. It engages three receptors that come online at different rates and do different jobs and scale differently — adjusting the raw milligrams is not a single, linear dial.

The predominant discourse regarding retatrutide anchors on its GIPR at 8.9x native, GLP-1R at 0.40x native, and glucagon at 0.34x native. This is a common wording trap, as those numbers are not about the drug's strength. They are the ratio of how much drug is needed to attach to those receptors vs. human levels — in a laboratory dish.

Beyond misconstruing those values to view them as indications of the drug's strength, Retatrutide does not work the same way as natural GLP-1, GIP, and glucagon — all of which fire in short bursts and clear from the blood within minutes: GLP-1 and GIP after a meal, glucagon during a fast or under stress. The human body's receptors are built for those brief blips followed by long quiet. Retatrutide holds all three of those receptors switched on around the clock.

GIPR (Glucose-Dependent Insulinotropic Polypeptide)

By 1 mg the GIP signal is already running at roughly twice what a large meal produces at its peak in obese individuals, and it holds there instead of fading² — a low dose is not a faint echo of natural GIP, but more GIP signal than the body ever makes after a meal, and signaled 24/7. The signal is stronger in more metabolically healthy individuals, and dampened in those with insulin resistance.

GLP-1R (Glucagon-like Peptide-1)

The body's own GLP-1 lasts only a minute or two before an enzyme clips it into an inactive form — it mostly talks to the gut and the nerves around it, barely reaching the brain directly. As a drug, retatrutide circulates intact and reaches appetite centers in the brain that natural GLP-1 rarely touches. A different route, not a louder version of the same one.¹²

GCGR (Glucagon)

In the body, glucagon is the fasting alarm that tells the liver to push sugar into the blood, in short pulses. Retatrutide runs that same liver signal, but alongside the GLP-1 and GIP arms that keep blood sugar in check. This yields glucagon's fat-burning and liver-clearing work without the blood-sugar rise it would cause on its own — and does so continuously, which is why the effect is pronounced even though it sits well below native-peak at lower doses."

The Nuances of Retatrutide Dosing

Reta's three arms — GLP-1, GIP, and Glucagon (GCGR) — all engage meaningfully at low doses. The 1 mg arm of the Phase 2 trial makes this clear: that cohort lost about 8% of body weight over 48 weeks, dropped liver fat by 51% in the people who had fatty liver, cut visceral fat by 16%, lowered triglycerides, and reduced appetite.¹ ⁶

The early saturation of GIPR driven fat-cell thermogenesis cannot produce that on its own. The appetite drop is the GLP-1R effect. The liver-fat and belly-fat loss are driven by the glucagon arm. The GIP arm adds insulin efficiency and a buffer against nausea induced by the GLP-1 component.

A receptor does not have to be full to do its job. The machinery it drives inside the cell maxes out long before the receptor itself fills, so the effect can run flat-out while occupancy is still tiny (the spare-receptor effect⁴). Retatrutide runs on this. At 1 mg the glucagon receptor sits under 1% occupied, and that sliver is already enough to cut liver fat in half in the people who started with a fatty liver⁶.

The common view that a low dose is mostly GIP with GLP-1 and glucagon still quiet is incorrect. For obese cohorts,all three arms are engaged at 1mg: 8% weight loss, the halved liver fat, the lower triglycerides, and the quieter appetite in that trial arm are a three-receptor result, not a GIP-only one.

What changes as the dose climbs is not which receptor switch on. GIP saturates early — the first 1 mg engages more of the GIP receptor than the next 11 mg combined.² A microdose is almost like a different drug, not a weaker one. GLP-1 appetite suppression climbs, but the effects become less distinct in the higher dose bands — yet side effects that cap tolerability rise with every step.

Glucagon climbs into territory the body never reaches on its own, adding the liver and visceral-fat work — and is the driver of HR increases. By 8 mg the curve already sits at about 94% of the weight loss 12 mg delivers¹, because the downstream system tops out before the receptors do.

None of those occupancy numbers are fixed, though. They are computed for the trial's body. Change the body, and the same milligrams land at a different occupancy and a different effect.

The Felt Effects of Retatrutide

What a given dose feels like depends on which of the three arms it leans on, and on the body it lands in. The same milligrams read as a quiet, mostly-metabolic experience in one person and an appetite-and-heart-rate experience in another.

Appetite and food noise go first. Within the first few days the background pull toward food quiets and meals get easier to stop. This rides the GLP-1 arm, so it is light at the bottom of the ladder and stronger higher up. A lighter or metabolically healthy body feels less of it at a given milligram and more of the heart-rate and metabolic side; a heavier body feels the appetite drop as the main event.

The body changes faster than the scale. Visceral and liver fat move early and out of proportion to weight, because the glucagon arm goes after them directly. The waist often loosens before the scale moves much, and a fatty liver is where the largest change lands even at a low dose. A liver that is already clean has no fat to lose, so the same arm shows up instead as rising ketones and a slightly warmer, more fat-burning baseline.

Energy is the effect that gets underestimated. Reta runs a deficit and pushes the body to burn at the same time, so a flat or wired-but-tired stretch is common. Protein, electrolytes, and sleep are the strongest levers against it. The fatigue guide and the retatrutide and NAD+ protocol carry the more advanced mitigation approaches.

Dose Escalation Effects

The cost climbs with the dose, and it splits by arm. The gut effects ride the GLP-1 arm, peak during titration, then ease.

The heart-rate cost is mostly the glucagon arm: GLP-1 on its own nudges heart rate up a little and then flattens, while glucagon carries the part that keeps climbing with the dose. Heart rate is also phenotype-coupled: near zero at 1 mg in the obese trial cohort, but +10 bpm or more at the same 1 mg in a leaner body from Phase 1b.

The burning or tingling in the hands and feet that can show up higher on the ladder tracks the dose rather than weight loss, and in the Phase 3 osteoarthritis trial it reached about 1 in 5 at 12 mg⁸. The mechanism is not settled — most likely a peripheral nerve effect of the drug class rather than one specific arm. It is usually mild, eases when the dose comes down, and tends to be worse where nerves are already compromised. Sustained glucagon can also slow the conversion of thyroid hormone into its active form, so cold plus foggy plus flat is the pattern that earns a Free T3 rather than just a TSH¹³.

For magnitude, the obese trial cohorts lost roughly 8% of body weight at 1 mg (Phase 2) and up to about 28% at 12 mg in the Phase 3 obesity trial at 80 weeks, with liver fat down by half at the bottom and by most at the top in the Phase 2 fatty-liver subgroup¹ ⁶. That is those cohorts' reading, and the Phase 3 weight figure is still company-topline. A lighter, leaner body reaches the same effect at fewer milligrams and pays more on the heart-rate side, so those percentages are a number to translate, not a forecast to copy.

How to Titrate, and the Consequences of Increasing Too Quickly

The final dose decides the endpoint. Titration decides whether the body can stay on long enough to reach it.

Reta's six-day half-life keeps plasma climbing for about three weeks after each step, so a heart-rate or nausea response can surface after the dose has already moved up. That sets the interval: each step needs four to five weeks before the next, and the trigger to climb is symptom resolution, not the calendar. Active nausea, reflux, constipation, a still-climbing resting heart rate, or broken sleep marks a body that has not caught up to the current dose, and a step added on top of that is what carries a workable dose into an intolerable one.

Going fast saves little and costs a lot. The trial ran the same maintenance dose with a slow ladder and a fast one. The fast 8 mg arm is the warning: nausea, vomiting, and diarrhea climbed to 30 to 35% and stayed there for the whole trial, while every other arm, including the slow 12 mg ladder, peaked and then settled into the single digits¹ ¹⁰. The reason is the nausea brake. The GIP arm runs an anti-nausea circuit, but it has to fire alongside a low GLP-1 load for a few weeks to wire in; a fast jump hits the nausea pathway hard before the brake is connected, and once that window closes, slowing down later does not rebuild it²¹. Fast titration buys a percent or two of extra weight loss for a large and lasting jump in side effects.

The bridge steps are the consequence: skipping them is where the trouble concentrates. The 4 mg to 8 mg jump is the hardest — the GLP-1 and glucagon arms climb fastest there, while the GIP brake is already maxed out and adds nothing more. A 5 or 6 mg step in between gives the gut and the heart somewhere to land.

Overweight but Not Obese

The most common person injecting reta is not the trial subject — typically 180 to 220 lb, a BMI in the high 20s to low 30s, with 20 to 40 lb to lose. The trial studied someone 50 to 70 lb heavier, and the lean-recomposition writeups describe someone much lighter. This middle range sits between the two, and three consequences follow.

Drug exposure runs higher per milligram than the 240 lb trial mean, roughly 10 to 25% more across this range⁹, so the trial's dose numbers read slightly hot against this body. Resting heart rate sits above the trial's near-zero reading too: the placebo-like +0.7 bpm at 1 mg is a 24-hour average that includes sleep, and a body in this range trends closer to +2 to +5 bpm at 1 mg and climbs from there²². And lean mass is lower relative to the trial cohort, so protecting it carries more weight than it does for a body with a large reserve.

Most of the available weight loss arrives in the 4 to 6 mg band, where the curve has already flattened and the side-effect and heart-rate cost climbs fastest above it. The Phase 3 obesity trial points the same way: in that cohort, the 4 mg dose was reached in a single step, produced about 19% weight loss at 80 weeks, and had dropout no higher than placebo. The magnitude is the obese cohort's, but the tolerability finding travels: a low dose, minimally titrated, does most of the work, with resting heart rate the variable to track weekly through the climb. Above that, 8 mg and up reads as a deliberate choice for a stubborn plateau rather than the default destination. No reta trial is dosed at this body, so this reads between the two trial groups, not from direct measurement.

Microdosing for Metabolic Health

Microdosing is its own goal, not a smaller version of the weight-loss plan. The target is metabolic: insulin sensitivity, visceral and liver fat, lipids, the markers of metabolic health rather than a number on the scale.

The low end of the ladder suits it well. At the bottom, the GIP arm (fat-cell handling and insulin efficiency) and the glucagon arm (the liver and visceral-fat work) are already on, while appetite suppression stays light and the heart-rate cost stays small, and the body sits near caloric balance instead of in a deep deficit. The 1 mg trial arm shows the markers moving at minimal cost: liver fat down 51% in people with fatty liver, visceral fat down 16%, triglycerides down, and ketones rising as the liver burns fat⁶.

The dose that does this tracks the body. For a heavier, metabolically average person the clean dose is around 1 mg. For a lean, metabolically healthy person it is lower, roughly 0.25 to 0.5 mg, because exposure is higher and the heart is more reactive at the same milligrams¹⁶. It runs weekly, the same schedule as the full dose.

These are mechanisms and biomarkers, not outcomes. Liver fat, visceral fat, lipids, ketones, and insulin are real and measured, but no retatrutide trial has tested insulin sensitivity or longevity as an endpoint. The case for microdosing for metabolic health rests on what the markers do, not on a trial that followed metabolic-health users for years.

Managing Fatigue, Hydration, and the Thyroid Flag

Reta runs two demands at once. It cuts intake, and it pushes the liver and other tissues to burn more. That double draw is why its fatigue tends to arrive earlier and harder than on semaglutide or tirzepatide. The first lever is the dose, not a supplement: active fatigue, nausea, or a high resting heart rate is the signal to hold the current step rather than climb into it.

The basics carry most of it. Protein stays high, at least 0.7 g per pound of body weight spread across the day, so the deficit comes off fat rather than muscle²⁴. Electrolytes stay up, sodium first, because these drugs blunt thirst and flush sodium, a common hidden cause of the tiredness and lightheadedness. The deeper fatigue playbook, including the energy-cofactor angle for the month 3 to 6 wall, is in the GLP-1 fatigue guide and the retatrutide and NAD+ protocol.

One flag stands out. Sustained glucagon signaling can slow the conversion of thyroid hormone into its active form: Free T3 drops while TSH reads normal, so a standard thyroid panel misses it¹³. Cold intolerance and brain fog stacked on top of fatigue is the pattern that warrants a Free T3, not just a TSH.

A short monitoring routine makes every later dose decision cleaner.

• Before starting: a week of resting heart rate and rhythm, fasting glucose and HbA1c and insulin, a lipid panel, liver enzymes, and a thyroid panel that includes Free T3. A personal or family history of medullary thyroid cancer or MEN2 rules the whole class out.
• On therapy: resting heart rate weekly through titration and every two weeks at maintenance, weight and waist weekly, and the lab panel each quarter. A smartwatch ECG check at each step past 6 mg adds a cheap margin where one is available. Pre-existing atrial fibrillation or structural heart disease is a strong reason not to start without a cardiologist's sign-off.
• When to hold or step down: resting heart rate more than 10 bpm above baseline for two weeks running, unresolved nausea from the prior step, or a new irregular rhythm. For the tingling in hands and feet at 8 to 12 mg, dropping to 4 to 6 mg eases it and 1 to 2 mg clears it.

Switching From Semaglutide or Tirzepatide

The glucagon arm is the catch. A year on tirzepatide builds tolerance to two of reta's three receptors, GIP and GLP-1, but none to glucagon, the arm that drives the heart-rate rise, the liver fat-burning, and the fat release. Carrying a high tirzepatide dose straight across to a matched reta dose lands that whole new system at once, which is behind the reports of heavy fatigue and flu-like weeks in people who jump from max-dose tirz to 4 mg or more of reta.

Reta starts at 1 to 2 mg regardless of the prior tirzepatide or semaglutide dose. The first weeks are about letting the glucagon arm settle, not re-proving the GLP-1 or GIP tolerance already in place. A heavy heart-rate rise or fatigue at the bridge dose is the signal to hold or drop back before climbing.

Coming Off Retatrutide

There are two ways down, and they are not the same. The first is not really coming off at all. Once a plateau is reached, spacing the same dose out, every other week for example, tends to hold the weight and the metabolic gains rather than hand them back, and it appears to spare muscle better than the active-loss phase did. It takes less drug to hold a plateau than to reach one. The evidence is thin and comes from semaglutide and tirzepatide rather than reta, a small uncontrolled case series, but reta sits in the same long-acting class, so spacing out is the move to try before stopping outright.

Fully stopping is the other path, and regain is the default, not a failure of willpower. Across the class, people put back the majority of the lost weight within a year of stopping, roughly two-thirds on the semaglutide and tirzepatide evidence, with most of it in the first months and about a quarter of the loss held¹⁸. Reta's regain pressure is likely steeper, because the glucagon-driven support for resting metabolism fades within weeks of the last dose while appetite returns and any lost muscle keeps daily burn low. No reta withdrawal trial has measured this yet, so the shape is borrowed from the other two.

Either way, the landing is the part that needs protecting. Protein at 0.7 g per pound and resistance training belong in from the start, not after the scale turns, and the lean-mass dip is usually an early decline that stabilizes rather than an endless slide²⁴. Strength holding or climbing is the signal that matters more than any single scale or scan number. The full taper and lower-dose-maintenance framework is in the stopping GLP-1s guide.

Clinical Data Limitations

Retatrutide is investigational. The first Phase 3 trials have reported (TRIUMPH-1 in obesity, TRIUMPH-4 in obesity with knee osteoarthritis, and TRANSCEND-T2D-1 in type 2 diabetes); the obesity-plus-T2D, cardiovascular, renal, and liver-disease trials read out through 2026 and 2027.

• No DXA fat:lean data yet. The dedicated body-composition (DXA) substudy sits in TRIUMPH-3 and has not reported. Tirzepatide's measured ~75:25 fat-to-lean loss split doesn't necessarily transfer.
• No published step-down maintenance protocol. Any high-to-mid-to-low taper rhythm is mechanism-derived, not measured.
• No head-to-head vs tirzepatide. TRIUMPH-5 (NCT06662383) will produce the first direct dose-matched comparison.
• No retatrutide-specific population PK by body weight. The lean-user math uses class analogy from semaglutide and tirzepatide PK literature, not direct retatrutide measurement.
• Long-term safety now reaches Phase 3 durations: 80 weeks in TRIUMPH-1, with a 104-week extension in the heavier subgroup. The dedicated cardiovascular and renal outcomes trial (around 10,000 participants) has not reported.

The microdose case is the strongest evidence position in the GLP-1 class. The 1 mg arm of Phase 2 produced direct measurement. The high-dose long-term safety case carries materially more uncertainty than tirzepatide or semaglutide do at comparable durations.

FAQ

Related Topics

• Retatrutide Deep Dive — full mechanism, trial cohorts, body-composition data
• Retatrutide vs. Tirzepatide — direct comparison
• Retatrutide Dual-Axis Protocol — advanced stacking for recomposition
• Retatrutide + NAD+ Protocol — cofactor layer during active dosing
• GLP-1 Hub — broader GLP-1 family coverage
• GLP-1 Dosing Optimizer — interactive frequency calculator with plasma curves
• GLP-1 Reconstitution Calculator — per-vial BAC water and syringe-unit charts for retatrutide
• Full Reconstitution Calculator — all peptides, cocktails, custom BAC volumes
• GLP-1 Muscle Preservation — protect muscle during weight loss

References

¹ Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023: 10.1056/NEJMoa2301972 — Phase 2 dose-response (1, 4, 8, 12 mg arms, 48 wk, non-diabetic obesity); per-arm-per-initial-dose split tables; HR Δ at 24 wk; AE temporal pattern (Figure S9); responder distributions.

² Hyperbolic saturation — receptor occupancy = [free drug] / ([free drug] + EC50). Standard Hill-equation pharmacology applied to retatrutide's free-drug Cav,ss and Coskun 2022 binding constants. The first 1 mg crosses the steepest portion of the GIP curve; subsequent dose increases produce diminishing returns. Retatrutide's GIP receptor binding constant is 16× lower (tighter) than tirzepatide's, which is why the GIP curve fills faster on retatrutide than the equivalent dose of tirzepatide would.

³ Tissue-threshold split — receptor density, downstream signal amplification, and per-tissue glucagon sensitivity differ across liver, visceral fat, sinus node, and subcutaneous fat. Thresholds derived from Phase 2 dose-response data and tissue-specific glucagon receptor pharmacology.

⁴ Downstream saturation / spare receptor — full physiological response often achieved at 10–20% receptor occupancy because the cell's downstream signaling pathway has its own ceiling. Standard receptor pharmacology principle, applied to incretin signaling.

⁵ White-fat futile calcium cycling — chronic GIPR engagement on white adipocytes triggers SERCA-mediated ER calcium leak; the pump runs continuously, burning ATP and forcing the cell to oxidize stored fat for fuel. Yu 2025 Cell Metabolism.

⁶ Sanyal AJ, et al. Retatrutide MASLD substudy. Nature Medicine 2024: s41591-024-03018-2 — 48-week MRI-PDFF liver fat reduction (51% at 1 mg, 86% at 12 mg); VAT and ASAT data; insulin and lipid panels; β-hydroxybutyrate as biomarker of hepatic fatty-acid oxidation.

⁷ Cardiac BMR cost — each 1 bpm of sustained resting HR adds 30–50 kcal/day from cardiac muscle work. Use raw HR Δ for this calculation, not placebo-subtracted (placebo arm shows real cardiovascular adaptation from weight loss + lifestyle counseling, so subtraction over-corrects for drug-attributable cost).

⁸ Eli Lilly press release, December 11, 2025 — TRIUMPH-4 Phase 3 results in obesity + osteoarthritis; 12 mg = 28.7% weight loss at 68 weeks. investor.lilly.com.

⁹ Population PK exposure shift by body weight — derived from class-analogous semaglutide and tirzepatide population-PK literature (Carlsson Petri 2018 Diabetes Therapy; Schneck 2024 CPT). Retatrutide-specific body-weight covariate not yet published; class analogy applied. A 70 kg user lands at roughly 1.4× the exposure of the ~110 kg trial cohort at the same nominal dose (about 1.15–1.2× versus an 85 kg reference); the steepest single-compound point is ~1.4× at 55 kg versus the 85 kg reference.

¹⁰ Within-pair titration analysis — Jastreboff 2023 supplementary tables S4 + S5, Figure 1A trajectory data, Figure S9 panel A AE temporal data. Slow vs fast titration compared at matched final maintenance dose for both 4 mg and 8 mg cohorts; waist-circumference-to-weight-loss ratios at week 4 used as quasi-DEXA proxy for fat-vs-lean distribution.

¹¹ Adaptation pathways (brainstem nausea circuit, sinus-node baroreflex) respond to rate of change in receptor occupancy; efficacy pathways respond to cumulative exposure over time. This is why slow titration produces fewer side effects at the same final dose.

¹² Coskun T, et al. Retatrutide discovery and receptor pharmacology. Cell Metabolism 2022: 10.1016/j.cmet.2022.07.002 — receptor binding constants (GIP EC50 0.0643 nM, GLP-1 0.775 nM, glucagon 5.79 nM); potency ratios vs native peptide (GIP 8.9× more potent than native, GLP-1 2.5× less potent, glucagon 2.9× less potent); full agonist at all three at cAMP signaling (E_max numbers in ref ¹⁵); 6-day half-life; structural design. Earlier framings of these numbers as "intrinsic efficacy multipliers" or "partial agonist" were a measurement-mislabel and are retracted.

¹³ T3 suppression on GLP-1 / GIP / glucagon agonism — caloric deficit and hepatic energy expenditure together downregulate T4-to-T3 conversion; Free T3 drops while TSH stays in range. See GLP-1 fatigue guide for monitoring.

¹⁴ Cross-class GIP binding affinity — retatrutide GIPR EC50 0.0643 nM (Coskun 2022) vs tirzepatide GIPR EC50 1.01 nM (Willard FS, et al. JCI Insight 2020;5(17): 10.1172/jci.insight.140532). Retatrutide's GIPR cAMP EC50 is roughly an order of magnitude lower than tirzepatide's, so meaningful GIP engagement happens at a fraction of the dose. The two values are comparable — both from low-receptor-density cAMP assays (Coskun 2022 explicitly used Willard 2020's method), with a small cross-lab offset (~1.2×, gauged from native-ligand controls) — so treat the ~16× as a ratio rather than an exact multiple. Both compounds are full cAMP agonists at GIPR; once engaged, each receptor fires at native-equivalent peak strength. Cross-compound receptor-occupancy percentages are deliberately not compared here: occupancy (pRO) is a modeled inference, not a measurement, and Willard 2020 cautions that "calculating pRO values has caveats." Binding affinity is the measured quantity.

¹⁵ Coskun 2022 mmc1 Table S1 + Table S2 — receptor functional activity at cAMP signaling. Retatrutide E_max at GIPR 103%, GLP-1R 110%, GCGR 104% of native peptide peak (full agonist at all three at cAMP signaling per the conclusions section: "LY3437943 is a full agonist at the GCGR, GIPR, and GLP-1R in the functional assays"). At a separate β-arrestin recruitment pathway at GLP-1R, reta E_max = 40% of native (partial / biased agonism), tirzepatide partial in the same direction, semaglutide full at both pathways. Earlier framings of "0.34× partial agonist at GCGR" or "0.4× softened agonist at GLP-1R" mistook potency ratios (EC50_LY ÷ EC50_native) for efficacy multipliers (E_max_LY ÷ E_max_native) and are retracted.

¹⁶ Coskun 2022 mmc3 Table 3 + mmc1 Table S8 — Phase 1 single-ascending-dose study (NCT03841630, n=45, conducted in Singapore). Population: 97.8% Asian, 93% male, mean weight 76.7 kg, mean BMI 26.3, healthy non-diabetic. Per-cohort baseline weight + BMI: 0.3 mg cohort 67.5 kg / BMI 23.2; 1 mg cohort 73.5 kg / BMI 26.1; 4.5 mg cohort 69.9 kg / BMI 23.2 (the leanest cohorts). Pulse rate 8-day average LSM CFB: placebo +5.0; 0.1 mg +2.4; 0.3 mg +7.6; 1 mg +10.3; 3 mg +16.7; 4.5 mg +25.2; 6 mg +19.3 (3 mg and above statistically significant vs placebo). Day 4–6 peak (Figure S4C) approximately 1.5–2× higher than the 8-day average. Returns toward baseline by day 29–43.

¹⁷ Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol 2024;13:494–503: 10.1002/psp4.13099. 39,644 samples, 5,802 participants, 19 studies. Two-compartment model with first-order absorption + elimination; F = 0.8 fixed; ka = 0.0373 /h; TVCL = 0.0329 L/h/70 kg; allometric exponent on CL = 0.8 (BW^0.8); allometric exponent on Vd = 1.0 with FFM + 0.482·FM scaling; mean t½ = 5.4 days; accumulation R at QW = 1.7×. Used as donor PopPK structure for the retatrutide PK bridge — the BW^0.8 allometric exponent is internally validated against retatrutide in Rosenstock 2023 arm pairs (4 mg ID2 at 108.3 kg vs 4 mg ID4 at 93.1 kg: predicted Cav,ss ratio 1.13, observed 1.18, 4.8% error), so the borrowing is tirz-prior, reta-confirmed rather than tirz-substituted.

¹⁸ Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. NEJM 2011;365:1597–1604: 10.1056/NEJMoa1105816. One year after diet-induced weight loss of about 13.5 kg, leptin remained 35% below baseline; ghrelin elevated; PYY suppressed; CCK suppressed; postprandial insulin reduced; hunger sustained above baseline. The hormonal adaptation pattern that drives regain is a 12-month story, not a transient.

¹⁹ Sinoatrial node chronotropy — direct Gs/cAMP/funny-channel signaling via GLP-1R at the heart's pacemaker. Lubberding AF, et al. Cardiovasc Res 2024 (direct mechanism demonstration); Petersen JD, et al. JAHA 2020 (esmolol crossover RCT confirming β-blockade independent and HRV unchanged — sympathetic activation is not the mediator). Pyke C, et al. 2014 monoclonal antibody localization confirms cardiac GLP-1R expression in human myocardium and SA node.

²⁰ Multi-receptor composite chronotropy — Goodman ML, et al. Br J Clin Pharmacol 2025 demonstrates that co-infusing a GLP-1 agonist with glucagon produces a perfectly additive HR response (+4 bpm + +4 bpm = +7 bpm at 60 min in n=12 lean males), confirming that glucagon drives chronotropy via a parallel pathway independent of GLP-1R cross-reactivity. For retatrutide at clinical doses, GLP-1R provides the baseline incretin HR rise (2–3 bpm); sparse but functional cardiac GCGR engagement drives the dose-scaling excess (3–6 bpm) unique to this class.

²¹ Local inhibitory network — GIPR-expressing neurons in the dorsal vagal complex (AP/NTS) are predominantly GABAergic with Gad1/Gad2 co-expression. Hayes MR, Borner T, De Jonghe BC. Diabetes 2021 + Zhang Q, et al. Neuron 2021 + Ludwig MQ, et al. Nat Metab 2021 (single-nuclei RNA-seq). Mechanism: GIPR activation → GABA release → local inhibition of GLP-1R-mediated emetic output. The brake circuit requires Hebbian synaptic plasticity to establish — neurons need to fire together at low intensity over time for the inhibitory connections to wire in. Fast titration skips this window. Cross-species emesis-blocking confirmed in musk shrew (Geisler/Borner 2020) and beagle + ferret (Takeda WO 2018/181864 A1).

²² Distinct cascade transduction states — Petersen JD, Sullivan TM. JCEM 2018 literature review documenting cardiac Gi-coupling shift in cardiomyocytes under chronic metabolic dysfunction. Obese sedentary cohorts show partial neutralization of Gs-driven chronotropy by upregulated Gi coupling, producing a fundamentally different Hill curve than the intact-Gs signaling of lean responsive cohorts. Same drug, same receptor occupancy, different cascade output. Confirmed by FDA NDA 215866 tirzepatide Clinical Pharmacology Review showing Japanese lean cohort amplified HR sensitivity at matched exposure.

²³ Adaptive thermogenesis offset — Long JZ, et al. 2025 demonstrates that chronic GCGR agonism downregulates hepatocyte PDE4B/4D phosphodiesterases, producing sustained cAMP-PKA signaling that preserves resting energy expenditure against the adaptive decline of weight loss. The mechanism is obesity-specific in mice; lean DIO mice show no GCGR-driven EE elevation. The practical claim is preservation against adaptive thermogenesis decline rather than baseline EE elevation. The chronic-tonic regime produces signals the pulsed regime cannot.

²⁴ Protein-leucine threshold for muscle protein synthesis — Mozaffarian D, et al. AJCN 2025 protein distribution and leucine threshold work. ≥1.6 g/kg/day total protein with ≥3 g leucine per meal across 3–4 meals optimizes muscle protein synthesis during caloric deficit.

²⁵ Tesamorelin pulsatile GH release — Stanley TL, et al. Tesamorelin for HIV-associated lipodystrophy. Lancet HIV 2019. Pulsatile growth-hormone release reduces visceral adipose tissue and liver fat.

²⁶ MOTS-c AMPK activation — Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism 2015. MOTS-c activates AMPK, the cellular energy sensor that responds to exercise.